Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 13/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567756 | 0.89 | S1PR1 (0.52) | KMT2AS1PR1S1PR4S1PR5SLC6A4 | |
| SCHEMBL25147645 | 0.86 | SIRT1 (0.56) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL1918133 | 0.85 | KMT2A (0.55) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL32666145 | 0.85 | KMT2A (0.55) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL4105569 | 0.84 | KMT2A (0.52) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL2566747 | 0.83 | KMT2A (0.62) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL1918737 | 0.83 | KMT2A (0.70) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL12923709 | 0.81 | KMT2A (0.49) | KMT2AS1PR1MEN1MAPTLMNA | |
| SCHEMBL1943980 | 0.79 | S1PR1 (0.82) | S1PR1S1PR4S1PR5 | |
| SCHEMBL2563862 | 0.79 | MAPT (0.52) | KMT2AS1PR1MEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222668-B1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2222668-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009078983-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | KMT2A 3974/4885S1PR1 1/4885MEN1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.